{"meta":{"query_hash":"61eb7b31e46f","filters":{"venue":"Biological Products Prevention Diagnosis Treatment"},"cohort_total":3,"direct_labels_cover":0,"predictions_cover":3,"exported":3,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/61eb7b31e46f","api":"https://metacan.xera.ac/api/v1/cohort?venue=Biological+Products+Prevention+Diagnosis+Treatment"},"results":[{"id":"W2888948683","doi":"","title":"Трансплантация фекальной микробиоты: возможные терапевтические подходы и вопросы правового регулирования","year":2015,"lang":"ru","type":"article","venue":"Biological Products Prevention Diagnosis Treatment","topic":"Clostridium difficile and Clostridium perfringens research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Fecal bacteriotherapy; Clostridium difficile; Diarrhea; Feces; Medicine; Disease; Intensive care medicine; Microbiology; Immunology; Biology; Gastroenterology; Pathology; Antibiotics","score_opus":0.21527336990834892,"score_gpt":0.37807039167735296,"score_spread":0.16279702176900404,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2888948683","genre_codex":"other","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.16077787,0.18300216,0.116894946,0.015649345,0.0051274407,0.00028848278,0.0011352511,0.0006164817,0.516508],"genre_scores_gemma":[0.7303828,0.080293976,0.083894305,0.0007099648,0.00092766754,0.00033431783,0.00032918868,0.00022475731,0.10290312],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9993672,0.00011175751,0.000032376913,0.00009225127,0.00032258205,0.00007380214],"domain_scores_gemma":[0.99933416,0.00016733508,0.00013217817,0.0000858149,0.00019140725,0.000088991255],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007193517,0.0003179489,0.00029990554,0.0020164398,0.0012736637,0.0025686705,0.0003466648,0.00073786266,0.013851579],"category_scores_gemma":[0.0014157548,0.00047152434,0.00032164712,0.00170711,0.0016936427,0.0012178163,0.0008667297,0.0012418405,0.0048457524],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021821735,0.000110984896,0.0032663534,0.0008202191,0.000050717314,0.0017333257,0.0022603509,0.0012006367,0.05886531,0.39543083,0.014099192,0.5219439],"study_design_scores_gemma":[0.00003047856,0.00011964962,0.0064767594,0.0002505981,0.000050752402,0.001968636,0.0010203302,0.0006822995,0.020703632,0.061467465,0.9071494,0.000080068465],"about_ca_topic_score_codex":0.0037991698,"about_ca_topic_score_gemma":0.0062992047,"teacher_disagreement_score":0.013851579,"about_ca_system_score_codex":0.0011278179,"about_ca_system_score_gemma":0.0018694184,"threshold_uncertainty_score":0.04633814},"labels":[],"label_agreement":null},{"id":"W2955764585","doi":"","title":"Безопасность биологических препаратов. Сообщение 2. Проблемы безопасности биоподобных препаратов","year":2016,"lang":"ru","type":"article","venue":"Biological Products Prevention Diagnosis Treatment","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biosimilar; Pharmacovigilance; Medicine; Infliximab; Interchangeability; Ulcerative colitis; Inflammatory bowel disease; Marketing authorization; Disease; Intensive care medicine; Pharmacology; Drug; Internal medicine; Bioinformatics","score_opus":0.10569599546046901,"score_gpt":0.33729123216130036,"score_spread":0.23159523670083135,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2955764585","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.05894608,0.08695616,0.18727474,0.013383403,0.008911226,0.0009402064,0.0027279963,0.002094366,0.63876575],"genre_scores_gemma":[0.45234638,0.05020865,0.18590863,0.0027031407,0.0015767883,0.0013941182,0.0011583654,0.00076823734,0.30393568],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99848324,0.00019594705,0.00010548779,0.00025184467,0.00083129195,0.00013227663],"domain_scores_gemma":[0.9990086,0.00025462158,0.00017966637,0.0001619188,0.0003197461,0.0000754409],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014579578,0.00048893975,0.0003673431,0.0016607059,0.001399385,0.0022029663,0.0005348228,0.0018469652,0.0297105],"category_scores_gemma":[0.0022201608,0.0007816509,0.00071393,0.0011011427,0.0013693678,0.0011669808,0.0009445093,0.002372422,0.018682575],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035930358,0.00016877319,0.0013415264,0.0016141715,0.000067395384,0.001824789,0.0013564489,0.0009839108,0.16239384,0.25387153,0.032265734,0.5437527],"study_design_scores_gemma":[0.00004286287,0.00012023906,0.0022944899,0.0001515217,0.000055599754,0.001685336,0.00021447976,0.00047135155,0.04756766,0.016488895,0.93082964,0.000077805315],"about_ca_topic_score_codex":0.0040773773,"about_ca_topic_score_gemma":0.004947756,"teacher_disagreement_score":0.0297105,"about_ca_system_score_codex":0.0011951136,"about_ca_system_score_gemma":0.001794148,"threshold_uncertainty_score":0.09939152},"labels":[],"label_agreement":null},{"id":"W4362674372","doi":"10.30895/2221-996x-2023-23-1-26-41","title":"Safety and immunogenicity of IMVAMUNE®, a third-generation vaccine based on the modified vaccinia Ankara (MVA) strain","year":2023,"lang":"en","type":"article","venue":"Biological Products Prevention Diagnosis Treatment","topic":"Poxvirus research and outbreaks","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Vaccinia; Smallpox; myalgia; Chills; Smallpox vaccine; Adverse effect; Vaccination; Modified vaccinia Ankara; Immunogenicity; Virology; Attenuated vaccine; Immunology; Surgery; Internal medicine; Immune system","score_opus":0.08164719609911085,"score_gpt":0.3061261695840588,"score_spread":0.22447897348494794,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362674372","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938916,0.004122055,0.0006157923,0.000080691985,0.000033031803,0.00005851909,0.000120820354,0.0000075705457,0.0010698381],"genre_scores_gemma":[0.99828124,0.0008067979,0.00021384153,0.000046287645,0.000032114018,0.00002035366,0.00017585396,0.0000023830119,0.00042101112],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99937755,0.00021634674,0.000060841747,0.00008271061,0.00021134736,0.000051159965],"domain_scores_gemma":[0.99883527,0.00040065637,0.00038009774,0.000097252734,0.00022917308,0.000057612757],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011000517,0.00027459994,0.00037243616,0.00022229721,0.00015131266,0.00044708588,0.00015663651,0.0004561943,0.0007378064],"category_scores_gemma":[0.0016308283,0.00010719285,0.0005794499,0.00017727037,0.00030623868,0.0003337245,0.00016709894,0.00055981736,0.00018315917],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.042818412,0.0080764145,0.20487772,0.002566258,0.0007371672,0.0017987331,0.0021168217,0.004886706,0.3241843,0.0008956796,0.0013375364,0.4057043],"study_design_scores_gemma":[0.0012547591,0.33257487,0.43492684,0.0002834466,0.0012372464,0.00693261,0.00070834113,0.004257682,0.19393773,0.000822866,0.022981824,0.000081775244],"about_ca_topic_score_codex":0.0002790132,"about_ca_topic_score_gemma":0.00011666431,"teacher_disagreement_score":0.0011000517,"about_ca_system_score_codex":0.00033882385,"about_ca_system_score_gemma":0.00036218777,"threshold_uncertainty_score":0.0058177114},"labels":[],"label_agreement":null}]}